A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Single-cell characterization of healthy fallopian tubes revealed shifts in cell and gene expression throughout the menstrual ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer diagnosis.

A U.S. bankruptcy judge has denied Johnson & Johnson's settlement plan relating to its baby powder products containing talc.

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

A judge rejected Johnson & Johnson’s talcum powder bankruptcy proposal, allowing talc ovarian cancer lawsuits to proceed in ...

A Houston bankruptcy judge has rejected Johnson & Johnson’s to use federal bankruptcy procedures to force a settlement with ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Shares of Johnson & Johnson ( JNJ -6.69%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m. ET. The drop ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.